---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002853"
form_type: "8-K"
ticker: "AHCO"
cik: "0001725255"
company_name: "AdaptHealth Corp."
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:36:36.057276+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# AdaptHealth guides FY2023 revenue $3.21-3.29B, adj. EBITDA $690-750M; Q4 prelim near prior ranges

## Summary
- FY2023 net revenue guidance $3.210B-3.290B; Adjusted EBITDA $690M-$750M; capex 9-11% of revenue.
- FY2022 net revenue expected near midpoint of $2.950B-$3.010B; Adjusted EBITDA near low end of $620M-$650M.
- Non-acquired net revenue growth for 2023 estimated at 8-10%, driven by stabilizing PAP device supply.
- CEO cites strong demand but notes cost-of-goods inflation and labor pressures across healthcare.
- Full Q4 and FY2022 results scheduled for release February 28, 2023.

## SEC filing metadata
- accession: 0001104659-23-002853
- form_type: 8-K
- ticker: AHCO
- cik: 0001725255
- company_name: AdaptHealth Corp.
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/tm233016d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002853
- JSON: https://secwatch.observer/filing/0001104659-23-002853.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002853.txt

## Key facts
- Earnings Releases
  AdaptHealth Corp. reported fiscal year 2023 results: revenue $3.210 billion to $3.290 billion. Guidance initiated.
  - Period: fiscal year 2023
  - Revenue: $3.210 billion to $3.290 billion
  - Guidance: initiated
  - Result: guidance update
  source text: Based on current business, market trends, and acquisitions completed to date, the Company is establishing initial guidance for fiscal year 2023 as follows: · Net revenue of $3.210 billion to $3.290 billion; · Adjusted EBITDA of $690 million to $750 million; and · Total capital expenditures are expected to be 9-11% of net revenue. Guidance for fiscal year 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm
- Earnings Releases
  AdaptHealth Corp. reported preliminary financial results for fourth quarter 2022.
  - Period: fourth quarter 2022
  - Result: preliminary results
  source text: ADAPTHEALTH PROVIDES Full-year 2023 Guidance AND Preliminary Commentary on Fourth Quarter 2022 REsults
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm
- Earnings Releases
  AdaptHealth Corp. reported full year 2022 results: revenue net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion.
  - Period: full year 2022
  - Revenue: net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion
  - Result: preliminary results
  source text: the Company anticipates net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.